4
Changes in Ownership
Roivant Sciences Ltd. Filed Acc 0001140361-25-038545
President & Immunovant CEO sold 851,383 shares at an average $16.99 ($14,467,502)
- President & Immunovant CEO acquired 851,383 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Venker Eric President & Immunovant CEO | 2025-10-15 | Option exercise 10b5-1 | +414,683 | $15.85 | $6,572,726 | 1,919,642 | D |
| Venker Eric President & Immunovant CEO | 2025-10-15 | Sale 10b5-1 | −414,683 | $16.93 | $7,020,583 | 1,504,959 | D |
| Venker Eric President & Immunovant CEO | 2025-10-16 | Option exercise 10b5-1 | +318,282 | $15.85 | $5,044,770 | 1,823,241 | D |
| Venker Eric President & Immunovant CEO | 2025-10-16 | Sale 10b5-1 | −318,282 | $17.05 | $5,426,708 | 1,504,959 | D |
| Venker Eric President & Immunovant CEO | 2025-10-17 | Option exercise 10b5-1 | +118,418 | $15.85 | $1,876,925 | 1,623,377 | D |
| Venker Eric President & Immunovant CEO | 2025-10-17 | Sale 10b5-1 | −118,418 | $17.06 | $2,020,211 | 1,504,959 | D |
| Derivatives | |||||||
| Venker Eric President & Immunovant CEO | 2025-10-15 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −414,683 | 436,700 | D | ||
| Venker Eric President & Immunovant CEO | 2025-10-16 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −318,282 | 118,418 | D | ||
| Venker Eric President & Immunovant CEO | 2025-10-17 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −118,418 | 0 | D | ||
| Open-market sales · 851,383 sh · avg $16.99 · $14,467,502 | |||||||
Loading xslF345X05/form4.xml…